How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

29,491 results for

Intravenous Drug Abuse

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. A Randomized, Prospective, Open Label, Active Control, Phase IV Study to Evaluate the Effects of Statin Monotherapy or Statin / Ezetimibe Combination Therapy on Hepatic Steatosis in Patients With Hyperlipidemia and Nonalcoholic Fatty Liver Disease

: A Randomized, Prospective, Open Label, Active Control, Phase IV Study to Evaluate the Effects of Statin Monotherapy or Statin / Ezetimibe Combination Therapy on Hepatic Steatosis in Patients With Hyperlipidemia and Nonalcoholic Fatty Liver Disease Actual Study Start Date : May 14, 2018 Estimated Primary Completion Date : January 2020 Estimated Study Completion Date : January 2020 Resource links provided by the National Library of Medicine related topics: related topics: available for: resources: Arms (...) A Randomized, Prospective, Open Label, Active Control, Phase IV Study to Evaluate the Effects of Statin Monotherapy or Statin / Ezetimibe Combination Therapy on Hepatic Steatosis in Patients With Hyperlipidemia and Nonalcoholic Fatty Liver Disease A Randomized, Prospective, Open Label, Active Control, Phase IV Study to Evaluate the Effects of Statin Monotherapy or Statin / Ezetimibe Combination Therapy on Hepatic Steatosis in Patients With Hyperlipidemia and Nonalcoholic Fatty Liver Disease

2018 Clinical Trials

82. Pharmaceutical Representative

are the least likely to receive free drug samples Typical drug sample recipient has health insurance and lives far above poverty line >25% ($16 billion) of drug company advertising ($57 billion) was spent on samples (2004) III. Precautions: Gifts Sunshine Act (U.S. regulation as of August 2013) Pharmaceutical Representative gifts over $10 are reported to a public list (with the provider's name) IV. Resources No Free Lunch V. References Images: Related links to external sites (from Bing) These images (...) Pharmaceutical Representative Pharmaceutical Representative Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Pharmaceutical

2018 FP Notebook

83. Pharmaceutical Industry

Pharmaceutical Industry Pharmaceutical Industry Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Pharmaceutical Industry Pharmaceutical (...) Industry Aka: Pharmaceutical Industry , Drug Manufacturer , Big Pharma From Related Chapters II. Efficacy: Manipulation of Pharma Sponsored Study Results Background Pharmaceutical companies have decades of work, billions of dollars of potential sales hinging on study results Newly introduced drugs are typically backed by studies that overestimate benefit and underestimate risk Methods of data manipulation Negative studies are not published Pharmaceutical supported studies with negative results

2018 FP Notebook

84. Animal-Derived Pharmaceuticals

Animal-Derived Pharmaceuticals Animal-Derived Pharmaceuticals Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Animal-Derived (...) Pharmaceuticals Animal-Derived Pharmaceuticals Aka: Animal-Derived Pharmaceuticals , Medications Derived from Animal Products , Animal-based Natural Product From Related Chapters II. Preparations: Derived from animal products Pig-derived products Dessicated (pig ) Pancreatic enzymes Horse Premarin (pregnant mares urine) Animal cartilage Gelatin capsules or gummy s Animal bones Calcium Animal blood Heme iron (Proferrin) Shellfish s (fish oil) Calcium (oyster shells) Sheep ( extract) Lanolin 3 III. Preparations

2018 FP Notebook

85. Pharmaceutical Representatives

are the least likely to receive free drug samples Typical drug sample recipient has health insurance and lives far above poverty line >25% ($16 billion) of drug company advertising ($57 billion) was spent on samples (2004) III. Precautions: Gifts Sunshine Act (U.S. regulation as of August 2013) Pharmaceutical representative gifts over $10 are reported to a public list (with the provider's name) IV. Resources No Free Lunch V. References Images: Related links to external sites (from Bing) These images (...) Pharmaceutical Representatives Pharmaceutical Representatives Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Pharmaceutical

2018 FP Notebook

86. Abuse-Deterrent Formulations of Opioids: Effectiveness and Value

and Drug Center Denver Health and Hospital Authority Professor, University of Colorado School of Medicine Economic Reviewer Alan G. White Managing Principal Analysis Group, Inc. Patient/Advocacy Reviewer Paul Gileno President US Pain Foundation ©Institute for Clinical and Economic Review, 2017 Page iv Evidence Report—Abuse-deterrent Formulations of Opioids: Effectiveness and Value Table of Contents Executive Summary ES1 1. Background 1 1.1 Introduction 1 2. The Topic in Context 6 3. Summary of Coverage (...) are used to treat acute and chronic pain that arises from a variety of causes, ranging from trauma to advanced illness. Every year, 100 million people in the U.S. suffer from pain, with 9-12% of these individuals experiencing pain that is considered chronic—lasting longer than three months. 1 Opioid therapy is an essential component of chronic pain management for many patients, but the addictive and euphoric properties of these drugs make patients vulnerable to misuse, abuse, addiction, and possible

2017 California Technology Assessment Forum

87. Responding to children and adolescents who have been sexually abused

) should be provided for HIV PEP , following initial risk assessment. Low Strong R3 A triple-therapy regimen (i.e. with three drugs) of ARVs is preferred but a two-drug regimen is also effective. Very low Conditional R4 Adherence counselling should be an important element in the provision of HIV PEP to survivors of sexual assault or rape. Very low Strong D. PREGNANCY PREVENTION AND MANAGEMENT AMONG GIRLS WHO HAVE BEEN SEXUALLY ABUSED QUALITY OF EVIDENCE STRENGTH OF RECOMMENDATION R5 Offer emergency (...) 20RESPONDING TO CHILDREN AND ADOLESCENTS WHO HAVE BEEN SEXUALLY ABUSED: WHO CLINICAL GUIDELINES iv C. HIV post-exposure prophylaxis treatment and adherence 23 D. Pregnancy prevention and management among girls who have been sexually abused 28 E. Post-exposure prophylaxis for curable and vaccine-preventable sexually transmitted infections 29 F. Psychological and mental health interventions in the short term and longer term 33 G. Ethical principles and human rights standards for reporting child or adolescent

2017 World Health Organisation Guidelines

88. Assess the Influence of Cenobamate on the PK of Cytochrome P450 (CYP) Probe Drugs as a Means of Predicting Drug-drug Interactions

Actual Study Start Date : February 22, 2017 Actual Primary Completion Date : July 3, 2017 Actual Study Completion Date : July 31, 2017 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: Single Group Drug: Cenobamate 12.5 mg q.d.(Days 13-26), 25 mg q.d. (Days 27-40), 50 mg q.d. (Days 41-54), 100 mg q.d. (Days 55-70), 150 mg q.d. (Days 71-84), 200 mg q.d. (Days 85-110) Drug: midazolam 2 mg midazolam syrup (...) Pharmacokinetic parameters Cmin [ Time Frame: bupropion (6 days), midazolam (24 hrs), omeprazole (24 hrs), warfarin (7 days) ] Will be determined for the probe drugs (and metabolites) when administered with or without cenobamate at steady state Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you

2017 Clinical Trials

89. A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib

medications within 28 days prior to check in Use of tobacco- or nicotine-containing products within 28 days prior to check in History of hyperbilirubinemia History of alcoholism or drug abuse within 2 years History of regular alcohol consumption exceeding 7 drinks/week for female subjects or 14 drinks/week for male subjects Positive hepatitis panel and/or positive human immunodeficiency virus (HIV) test Contacts and Locations Go to Information from the National Library of Medicine To learn more about (...) Date : September 17, 2018 Actual Primary Completion Date : December 21, 2018 Actual Study Completion Date : December 28, 2018 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: Part A Tucatinib plus Itraconazole Drug: tucatinib 300mg dose, orally administered Drug: itraconazole 200mg dose Experimental: Part B Tucatinib plus Rifampin Drug: tucatinib 300mg dose, orally administered Drug: rifampin 600mg dose

2018 Clinical Trials

90. A Study of an Investigational Drug to See How it Affects the People With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes) Compared to an Approved Drug Used to Treat People With Parkinson's Disease Complicated by Motor Fluctuations ("

Complicated by Motor Fluctuations Actual Study Start Date : December 19, 2018 Estimated Primary Completion Date : March 24, 2020 Estimated Study Completion Date : March 24, 2020 Resource links provided by the National Library of Medicine related topics: related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: APL-130277 APL-130277: Part A- determine the dose; Part B- 28-day repeat dosing at the dose determined in Part A Drug: APL-130277 APL-130277: Part (...) quetiapine or clozapine) or dopamine depleting agents. Subjects receiving anti depressants must be on a stable daily dose for at least 8 weeks prior to SV1. The subject has a current diagnosis or history of substance abuse (excluding nicotine and caffeine) or alcohol abuse (in the opinion of the investigator) < 6 months prior to SV1. The recreational use of cannabinoids and hallucinogenic are excluded, as well any use of a sublingual formulation of any drug. Subject has a history of malignancy within 5

2018 Clinical Trials

91. A Fixed-Sequence, Drug-Drug Interaction Study Between Multiple Oral Doses of Inarigivir Soproxil and a Single Oral Dose of Midazolam in Healthy Subjects

laboratory, electrocardiogram (ECG) and vital signs, as judged by the PI Willing and able to sign the ICF Exclusion Criteria: Employee of PRA or the Sponsor History of relevant drug and/or food allergies Using tobacco products within 60 days prior to the first drug administration History of alcohol abuse or drug addiction (including soft drugs like cannabis products) Positive drug and alcohol screen (opiates, methadone, cocaine, amphetamines [including ecstasy], cannabinoids, barbiturates (...) that may impact safety assessments, in the opinion of the PI Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03493698 Locations Layout table for location information Netherlands University Medical Center Groningen Groningen, Netherlands Sponsors

2018 Clinical Trials

92. A Study Evaluating Drug-Drug Interaction (DDI) Between HSK3486 Injectable Emulsion and Rifampin Capsules

; In receipt of any one of the following medications or treatments during screening/baseline: History of drug abuse or any signs of chronic benzodiazepines use (such as insomnia, anxiety, spasms) within 3 months prior to screening, or a positive urine drug test during baseline; Participated in clinical trials involving any medications or medical devices within 3 months prior to screening, or subjects who have participated in 3 or more drug clinical trials within the past year; In receipt of rifampin within (...) Recruitment Status : Not yet recruiting First Posted : November 29, 2018 Last Update Posted : February 25, 2019 See Sponsor: Sichuan Haisco Pharmaceutical Group Co., Ltd. Information provided by (Responsible Party): Sichuan Haisco Pharmaceutical Group Co., Ltd. Study Details Study Description Go to Brief Summary: This is a Phase I, single-center, open-label, randomized,two-way crossover, propofol-controlled, two-stage study evaluating the safety and pharmacokinetics/pharmacodynamics of IV maintenance dose

2018 Clinical Trials

93. Treatment Effects of Chinese Medicine (Yi-Qi-Qing-Jie Herbal Compound) Combined With Immunosuppression Therapies in Patients of IgA Nephropathy With High-risk of ESRD

Library of Medicine related topics: resources: Arms and Interventions Go to Arm Intervention/treatment Experimental: Combination Therapy Optimized supportive care, oral granular infusion of Yi-Qi-Qing-Jie herbal compound, prednisolone plus intravenous cyclophosphamide. Drug: The Yi-Qi-Qing-Jie Herbal Compound Patients will receive granular infusion of Yi-Qi-Qing-Jie herbal compound twice a day which composed of astragalus, angelica root, lonicera, rheum palmatum, etc, with the effect of reinforcing Qi (...) or lactation History of anaphylactic reactions or intolerance to study medications History of drug, alcohol, or chemical abuse Inability to comply with study and follow-up procedures Enrolled in other studies Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number

2018 Clinical Trials

94. Finding Quality Addiction Care in Canada: Drug and Alcohol Treatment Guide

be a better fit for you than others. Look for someone who has been trained to provide these therapies. 5. What are your qualifications and credentials? Look for one of the following credentials: doctor (M.D.), psychiatrist (M.D.), addiction medicine specialist (M.D.); licensed/ registered psychologist (Ph.D., Psy.D., M.A., M.Sc.), licensed/registered social worker (B.S.W. and M.S.W.), licensed/registered psychotherapist or counsellor (R.C.T.), National Native Alcohol and Drug Abuse Program (NNADAP) worker (...) relationships, work, school, social activities)? Source: Diagnostic and Statistical Manual (DSM 5) If you are concerned about your own or someone else’s alcohol or other drug use, you can get a full assessment by an addiction or healthcare provider. It is best to be assessed by someone with specialized training in alcohol and other drug treatment. Who can help? Professionals with the following credentials can help if they are also trained in addiction treatment. • Medical doctors (M.D.) • Addiction Medicine

2017 Canadian Centre on Substance Abuse

95. Complex regional pain syndrome/reflex sympathetic dystrophy medical treatment guideline.

medications, and it should generally be used in conjunction with manipulative and physical therapy/rehabilitation. Refer to the Division's for indications, evidence, and time frames. Biofeedback Biofeedback is a form of behavioral medicine that helps patients learn self-awareness and self-regulation skills for the purpose of gaining greater control of their physiology, such as muscle activity, brain waves, and measures of autonomic nervous system activity. Stress-related psycho-physiological reactions may (...) maximum medical improvement (MMI) care, refer to Section J.4, Maintenance Management, Injection Therapy, in the original guideline document. Sympathetic Injections See the original guideline document for description, indications, special considerations, complications, contraindications, relative contraindications, drugs affecting coagulations, and treatment parameters, as well as time to produce effect, frequency, and optimum and maximum duration of treatments. Peripheral Nerve Blocks

2017 National Guideline Clearinghouse (partial archive)

96. Guidelines for the Safe Management and Use of Medications in Anaesthesia Background Paper

statement with the ACSQHC supporting user-applied labelling standardisation for all injectable medicines and fluids 4 . In New Zealand PHARMAC is considering labelling recommendations. 3.2.3 With the increasing use of infusions for anaesthesia as well as for regional analgesia there is the potential for drug errors to occur. To minimise these errors, it is advisable to ensure that devices delivering intravenous medications are readily differentiated from those delivering local anaesthetics. Colour (...) of the local jurisdictional authority, the anaesthetist must be able to directly and independently access sufficient quantities of critical drugs. Such drugs would include propofol, adrenaline, muscle relaxants, and vasopressors. Page 3 PS51 BP 2018 3.5 Interruptions to supply – Recently, availability of a number of medications has been restricted due to problems with manufacture and supply, or concerns about potential contamination. Development of an “essential medicines list” has been proposed but cannot

2017 Australian and New Zealand College of Anaesthetists

97. Guidelines for the Safe Management and Use of Medications in Anaesthesia

of controlled medicines should be according to jurisdictional requirements. 5.9 INTRAVENOUS INFUSION OF MEDICATIONS 5.9.1 Wherever practicable infusion pumps and syringe drivers used for the administration of intravenous drugs should be standardised within an institution. Page 7 PS51 2018 5.9.2 When drugs are given by infusion, the patient end of the infusion line should be labelled and precautions taken with one-way valves to avoid any siphoning of the infused drug. Valve design should (...) this information in the anaesthesia record or patient’s drug administration chart, and any legally required register of drug dispensing. ? To minimise the opportunities for substance abuse and/or diversion. 4.2 Medical practitioners providing anaesthesia should have a detailed understanding of the pharmacology of the medications they prescribe or administer, together with an understanding of potential complications of drug administration and management of such complications. 4.3 Medical practitioners providing

2017 Australian and New Zealand College of Anaesthetists

98. Management of Suspected Opioid Overdose with Naloxone by Emergency Medical Services Personnel

) is similar in efficacy to 2 mg of IM naloxone, 2 mg of a lower concentration formulation of IN naloxone (2 mg/5 mL) is less effective than the same dose IM but associated with decreased risk of agitation and/or irritation. The 2 mg/5 mL formulation of IN naloxone studied in this trial is lower than concentrations used in the United States. In both trials, IN naloxone was associated with increased likelihood of rescue naloxone use. Although one RCT and two observational studies evaluated intravenous (IV (...) or illicit opioids exceeded 33,000, the highest number on record. 3 Of recent concern is whether dosing guidelines are sufficient for reversing overdose related to highly potent synthetic opioids (e.g., fentanyl and fentanyl analogues). 3,5-9 Field Treatment of Suspected Opioid Overdose With Naloxone Naloxone can be administered by the intravenous (IV), intramuscular (IM), subcutaneous (SC), intranasal (IN), endotracheal (ET), nebulized/inhalational, buccal, or sublingual routes. 10 The U.S. Food

2017 Effective Health Care Program (AHRQ)

99. Drug and Alcohol Abuse amongst Anaesthetists - Guidance on Identification and Management 2

to access specialist treatment facilities for substance abuse disorders than other speciality groups [6, 8, 14, 15]. Anaesthetists are more likely to abuse opioids as a drug of choice, to abuse drugs intravenously and to be addicted to more than one drug [6, 16]. Some of those in treatment actually cited drug availability or access as a reason for choosing anaesthesia as a career [14]. In 2007, 66% of the General Medical Council (GMC) annual caseload involved health problems – 43% involved alcohol abuse (...) professional. Critical Care Medicine 2007; 35 (Suppl 2): S106-16. 25. O’Connor P, Spickard Jr A. Physician impairment by substance abuse. Medical Clinics of North America 1997; 81: 1037-52. 26. Berge K, Seppala MD, Schipper AM. Chemical dependency and the physician. Mayo Clinic Proceedings 2009; 84: 625-31. 27. American Society of Anesthesiologists Committee on Occupational Health. Model curriculum on drug abuse for residents in anesthesiology. www.asahq.org/clinical/curriculum.pdf (accessed 15/10/2009

2011 Association of Anaesthetists of GB and Ireland

100. Evidence Map - Art Therapy

Evidence Map - Art Therapy 4 July 2019 Prepared for: Department of Veterans Affairs Veterans Health Administration Health Services Research & Development Service Washington, DC 20420 Prepared by: Evidence Synthesis Program (ESP) Center West Los Angeles VA Medical Center Los Angeles, CA Paul G. Shekelle, MD, PhD, Director Evidence Map of Art Therapy Authors: Principal Investigators: Isomi M. Miake-Lye, PhD Paul G. Shekelle, MD, PhD Co-Investigators: Eric A. Apaydin, PhD Selene S. Mak, MPH, PhD (...) Evidence Map Evidence Synthesis Program 1 EVIDENCE REPORT INTRODUCTION Many Veterans desire complementary and integrative health or alternative medicine modalities, and art therapy is one such option. Given VA’s desire to promote evidence-based practice, this evidence mapping project aims to help provide guidance to VA leadership about the distribution of evidence on art therapy to inform policy and future directions for art therapy in VA. The National Organization for Arts in Health (NOAH) identifies

2019 Veterans Affairs Evidence-based Synthesis Program Reports

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>